Position statement reports standardized quality of life assessment protocols in urticaria patients, highlighting the necessity of validated disease-specific instruments.
The European Academy of Dermatology and Venereology (EADV) Task Forces on quality of life (QoL) and patient‐oriented outcomes and on urticaria and angioedema recommendations for the assessment of Health‐related (HR) QoL in all patients with urticaria in research and practice are as follows: to use the DLQI for adults and the CDLQI for children as dermatology‐specific and the CU‐Q2oL as a disease‐specific HRQoL instruments in urticaria; to use generic instruments to provide comparison of data on urticaria with non‐dermatologic diseases, or to compare with healthy volunteers or the general population; to select validated HRQoL instruments with appropriate age limits; to present exact numeric data for HRQoL results; correct title of any HRQoL instrument should be used, along with its correct abbreviation and the reference to its original publication, where possible. The EADV TFs discourage the use of non‐validated HRQoL instruments and modified HRQoL instruments that have not undergone standard validation.
No takes yet. Share an insight, caveat, or question.
Chernyshov et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: